ascopubs.org

BXQ-350, a novel sphingolipid metabolism modulator, in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal cancer (mCRC) patients: A phase 1b/2 ...

A phase 2 study of intravenous pembrolizumab and intratumorally injected autologous dendritic cells (DCs) in refractory colorectal cancer (CRC). This is an ASCO Meeting Abstract from the 2025 ASCO ...
Medical Xpress

Molecular Function: sphingolipid metabolic process

A new study led by researchers at Mount Sinai Health System has identified distinct biological signatures in patients with mild Crohn's disease, offering a potential pathway toward more personalized ...
ascopubs.org

BXQ-350 efficacy and safety evaluation in first line mCRC patients: A phase 1b/2 study of BXQ-350, a first-in-class sphingolipid metabolism modulator, in combination with ...

Cracking the code: Clinical predictors of brain metastases in colorectal cancer. This is an ASCO Meeting Abstract from the 2026 ASCO Gastrointestinal Cancers Symposium. This abstract does not include ...